Aktienanalyse zu Bio Green Med Solution Inc (BGMS)BGMSBio Green Med Solution Inc

Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., is a diversified company engaged in both the fire protection and biopharmaceutical industries. It develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. It provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel. It operates in the Healthcare sector.

Currently, Bio Green Med Solution Inc (BGMS) is not a strong buy due to its recent performance and financial instability. The stock has a current price of $0.86, which is significantly down 39.01% year-to-date and 41.89% over the past year. Additionally, the RSI is at 39.275, indicating that the stock is nearing oversold territory but is not yet a clear buy signal. The company has reported negative earnings with a forward P/E of 0 and a gross margin of 23.51%, which is low compared to industry standards. The main risk is the company's high debt levels and recent losses, with a net income of -425000 in Q2 2026, suggesting ongoing financial challenges that could affect future performance.